MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (MOR.F) Prime Standard Segment; MDAX & TecDAX; (MOR) and Incyte (INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation (ASCT).

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

I-Mab (IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, and MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today jointly announced that the first patient has been dosed in a phase 3 clinical study in mainland China to evaluate MorphoSys’ investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (r/r MM). Under a licensing agreement with MorphoSys, I-Mab has exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Taiwan, Hong Kong and Macao.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 21, 2020 / MorphoSys (FSE:MOR)(Prime Standard Segment; MDAX & TecDAX)(NASDAQ:MOR) announced today the appointment of Roland Wandeler, Ph.D., as Chief Commercial ...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.

Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

MorphoSys Reports First Quarter 2020 Results Q1 Positively Impacted by Upfront Payment of Incyte Collaboration Conference call and webcast (in English) to be held on May 7, 2020 at 2:00pm CEST (1:00pm ...

Conference call and webcast (in English) tomorrow, March 19, 2020 at 2:00pm CET (1:00pm GMT/9:00am EDT) Key pipeline and corporate development updates: Tafasitamab (MOR208): Priority Review for BLA submission ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 14, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announced today that multiple abstracts from the Company's tafasitamab program ...

MorphoSys (ETR:MOR) has had a great run on the share market with its stock up by a significant 24% over the last...

All Proposed Resolutions Approved PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 27, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) announced today that its shareholders approved ...

Wilmington-based Incyte Corp. has received the green light to provide a $750 million upfront payment to German biotech MorphoSys AG as part of a joint collaboration and licensing agreement. The deal, announced in January, won antitrust clearance from the Federal Trade Commission. The deal required the OK from the FTC as well as the German and Austrian antitrust authorities.

NEW YORK, NY / ACCESSWIRE / March 19, 2020 / MorphoSys AG (NASDAQ:MOR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 19, 2020 at 2:00 PM Eastern ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 12, 2020 / MorphoSys AG (FSE:MOR) Prime Standard Segment, MDAX & TecDAX (NASDAQ:MOR) will publish its results for the financial year 2019 on March 18, 2020 ...

MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 27, 2020 / MorphoSys (FSE:MOR)(Prime ...

New two-year follow-up data (November 30, 2019 cut-off) of L-MIND trial corroborate previously reported primary analysis Updated IRC efficacy outcomes include objective response rate (ORR) of 58.8%, complete ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 30, 2020 / MorphoSys (FSE:MOR)(Prime Standard Segment; MDAX & TecDAX)(NASDAQ:MOR) will publish its results for the first quarter of 2020 on May 6, 2020 at 10:00pm ...

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 6, 2020 / MorphoSys AG (MOR)(Prime Standard Segment; MDAX & TecDAX)(MOR) provided an update on its business and the measures the Company is taking to mitigate the impact of the rapidly evolving global COVID-19 pandemic on its employees, patients and the broader community. "The well-being of our employees and patients is our top priority," said Jean-Paul Kress, M.D., CEO and Chairman of the MorphoSys Management Board. While we are working closely with the sites and our investigators to mitigate the impact of the COVID-19 pandemic on our clinical studies and to continue delivering the medicines our patients desperately need, we are putting their safety and that of the site personnel first.